Day: January 17, 2026

How Does Tirzepatide Break Barriers in Genetic Obesity and Real-World Care? In the evolving landscape of metabolic therapies, Tirzepatide has transcended conventional weight loss and glucose control—emerging as a trailblazer in treating genetic obesity and delivering consistent real-world results. As a dual GIP/GLP-1 receptor agonist, this peptide now commands 57.9% of U.S. GLP-1 prescriptions (Q3